Compugen Cash Conversion Cycle from 2010 to 2024

CGEN Stock  USD 1.61  0.09  5.92%   
Compugen Cash Conversion Cycle yearly trend continues to be very stable with very little volatility. Cash Conversion Cycle is likely to grow to 32.62 this year. During the period from 2010 to 2024, Compugen Cash Conversion Cycle quarterly data regression pattern had sample variance of 65.3 B and median of (1,510). View All Fundamentals
 
Cash Conversion Cycle  
First Reported
2010-12-31
Previous Quarter
31.07098678
Current Value
32.62
Quarterly Volatility
255.5 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Compugen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Compugen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 452.2 K, Interest Expense of 29.4 K or Selling General Administrative of 6.6 M, as well as many indicators such as Price To Sales Ratio of 4.98, Dividend Yield of 0.0 or PTB Ratio of 3.68. Compugen financial statements analysis is a perfect complement when working with Compugen Valuation or Volatility modules.
  
Check out the analysis of Compugen Correlation against competitors.
To learn how to invest in Compugen Stock, please use our How to Invest in Compugen guide.

Latest Compugen's Cash Conversion Cycle Growth Pattern

Below is the plot of the Cash Conversion Cycle of Compugen over the last few years. It is Compugen's Cash Conversion Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Compugen's overall financial position and show how it may be relating to other accounts over time.
Cash Conversion Cycle10 Years Trend
Pretty Stable
   Cash Conversion Cycle   
       Timeline  

Compugen Cash Conversion Cycle Regression Statistics

Arithmetic Mean(105,786)
Geometric Mean2,641
Coefficient Of Variation(241.57)
Mean Deviation167,490
Median(1,510)
Standard Deviation255,547
Sample Variance65.3B
Range734.6K
R-Value(0.25)
Mean Square Error66.1B
R-Squared0.06
Significance0.38
Slope(14,027)
Total Sum of Squares914.3B

Compugen Cash Conversion Cycle History

2024 32.62
2023 31.07
2022-27.8 K
2021-61.5 K
2019-733.9 K
2017 -1509.88
2016 -5421.51

About Compugen Financial Statements

Compugen investors utilize fundamental indicators, such as Cash Conversion Cycle, to predict how Compugen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Cash Conversion Cycle 31.07  32.62 

Pair Trading with Compugen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Compugen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Compugen will appreciate offsetting losses from the drop in the long position's value.

Moving together with Compugen Stock

  0.88VALN Valneva SE ADRPairCorr
  0.64VRAX Virax Biolabs GroupPairCorr

Moving against Compugen Stock

  0.84BMY Bristol Myers Squibb Aggressive PushPairCorr
  0.77ESPR Esperion TherapeuticsPairCorr
  0.69GILD Gilead SciencesPairCorr
  0.66DRUG Bright Minds BiosciencesPairCorr
  0.62NBY NovaBay PharmaceuticalsPairCorr
The ability to find closely correlated positions to Compugen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Compugen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Compugen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Compugen to buy it.
The correlation of Compugen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Compugen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Compugen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Compugen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Compugen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Compugen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Compugen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Compugen Stock:
Check out the analysis of Compugen Correlation against competitors.
To learn how to invest in Compugen Stock, please use our How to Invest in Compugen guide.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Compugen. If investors know Compugen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Compugen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.03
Revenue Per Share
0.48
Quarterly Revenue Growth
3.461
Return On Assets
(0.03)
Return On Equity
(0.16)
The market value of Compugen is measured differently than its book value, which is the value of Compugen that is recorded on the company's balance sheet. Investors also form their own opinion of Compugen's value that differs from its market value or its book value, called intrinsic value, which is Compugen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Compugen's market value can be influenced by many factors that don't directly affect Compugen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Compugen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Compugen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Compugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.